Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker Tags: Original Study Source Type: research
More News: Cutaneous T cell lymphoma | Hematology | Leukemia | Lymphoma | Mycosis Fungoides | Myeloma | Study | T-cell Lymphoma